Sustainability at Biocon
Generics : API - the building blocks
API Business: Overview
Among world's largest manufacturers of immunosuppressant &
statin APIs; leadership in Fermentation based APIs
API: Growth Drivers across Strategic Priorities
Expanding beyond
fermentation-based APIs
(e.g. peptides, potent APIs)
Product
Expertise in fermentation technology, large scale chromatography &
synthetic chemistry
Pipeline
Balanced portfolio across cardiovascular, anti-diabetes,
immunosuppressants, high potent API & few niche molecules for
hospitals/institutions
Consistent track record of quality compliance & regulatory approvals
(U.S. FDA, EMA, TGA Australia, Health Canada, Cofepris Mexico)
اشا
$65b
Global Generic API
Market Size 2022E*
40+
APIs
Investing in R&D - continuous
Regional
Expansion
manufacturing, bio
transformation
• Augmenting capacities & capabilities:
Immunosuppressants
(Vishakhapatnam)
Synthetic API (Hyderabad)
Manufacturing
Expansion
Additional fermentation capacities
(Bengaluru)
Base
Business
700+
API
customers
75+
Countries served
by API across US,
Europe & large
emerging markets
*Source: Global Industry Analysts Inc.'s 'Active Pharmaceutical Ingredients (API) - Global Market Trajectory & Analytics' Report, March 2022
Biocon 1
• Expanding in
select key
markets
•
Large customer
acquisitions
· De-risking dependence
for critical
intermediates
日日日
5
Facilities in
India
10View entire presentation